BG101145A - USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA - Google Patents

USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA

Info

Publication number
BG101145A
BG101145A BG101145A BG10114597A BG101145A BG 101145 A BG101145 A BG 101145A BG 101145 A BG101145 A BG 101145A BG 10114597 A BG10114597 A BG 10114597A BG 101145 A BG101145 A BG 101145A
Authority
BG
Bulgaria
Prior art keywords
same
physiologically
salts
competible
adenosyl
Prior art date
Application number
BG101145A
Other languages
Bulgarian (bg)
English (en)
Inventor
Laszlo Szabo
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of BG101145A publication Critical patent/BG101145A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BG101145A 1994-07-16 1997-01-17 USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA BG101145A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4425280A DE4425280C2 (de) 1994-07-16 1994-07-16 Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden
PCT/EP1995/002598 WO1996002252A1 (de) 1994-07-16 1995-07-05 VERWENDUNG VON (S)-ADENOSYL-L-METHIONIN (SAMe) UND DESSEN PHYSIOLOGISCH VERTRÄGLICHEN SALZEN ZUR BEHANDLUNG VON REPERFUSIONSSCHÄDEN, DIE DURCH TEMPORÄRE FOKALE ISCHÄMIE AUSGELÖST WERDEN

Publications (1)

Publication Number Publication Date
BG101145A true BG101145A (en) 1997-08-29

Family

ID=6523426

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101145A BG101145A (en) 1994-07-16 1997-01-17 USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA

Country Status (18)

Country Link
US (1) US5776911A (hr)
EP (1) EP0771202A1 (hr)
JP (1) JPH10502652A (hr)
KR (1) KR970704442A (hr)
AU (1) AU2927195A (hr)
BG (1) BG101145A (hr)
CA (1) CA2195345A1 (hr)
CZ (1) CZ12297A3 (hr)
DE (1) DE4425280C2 (hr)
FI (1) FI970165A (hr)
HR (1) HRP950405A2 (hr)
HU (1) HUT76834A (hr)
IL (1) IL114540A0 (hr)
NO (1) NO970185L (hr)
PL (1) PL318318A1 (hr)
SI (1) SI9520087A (hr)
WO (1) WO1996002252A1 (hr)
ZA (1) ZA955865B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19515275A1 (de) * 1995-04-26 1996-10-31 Knoll Ag Neue Verwendung von (S)-Adenosyl-L-methionin(SAMe)
IT1317920B1 (it) * 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
US8841344B2 (en) 2002-10-03 2014-09-23 Hill's Pet Nutrition, Inc. Method of using omega-3 fatty acids
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
AU2006237346B2 (en) * 2005-04-20 2011-04-07 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
WO2009114939A1 (en) 2008-03-17 2009-09-24 National Research Council Of Canada Aromatic prenyltransferase from hop

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173990B (it) * 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale
JPH0770235B2 (ja) * 1988-06-24 1995-07-31 株式会社東芝 不揮発性メモリ回路装置
JPH02290896A (ja) * 1989-04-28 1990-11-30 Fuji Kagaku Kogyo Kk 新規なｓ―アデノシルメチオニン誘導体

Also Published As

Publication number Publication date
CZ12297A3 (cs) 1998-04-15
JPH10502652A (ja) 1998-03-10
ZA955865B (en) 1997-01-14
MX9700439A (es) 1998-05-31
NO970185D0 (no) 1997-01-15
SI9520087A (en) 1997-08-31
US5776911A (en) 1998-07-07
EP0771202A1 (de) 1997-05-07
HRP950405A2 (en) 1997-10-31
IL114540A0 (en) 1995-11-27
NO970185L (no) 1997-03-12
KR970704442A (ko) 1997-09-06
DE4425280A1 (de) 1996-01-18
PL318318A1 (en) 1997-06-09
FI970165A0 (fi) 1997-01-15
HU9700130D0 (en) 1997-02-28
AU2927195A (en) 1996-02-16
FI970165A (fi) 1997-03-14
WO1996002252A1 (de) 1996-02-01
HUT76834A (en) 1997-11-28
CA2195345A1 (en) 1996-02-01
DE4425280C2 (de) 1997-05-07

Similar Documents

Publication Publication Date Title
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
MX9700557A (es) Dihidrobenzofuranos.
YU15299A (sh) Farmaceutski sastavi
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
ZA200007642B (en) Treatment of airborne microorganisms.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
TR199900505T2 (hr)
YU18801A (sh) Eletriptan hidrobromid monohidrat
BG101145A (en) USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA
BG100248A (en) Squalene synthetase inhibitors
GB2324091A (en) Metalloproteinase inhibitors
ZA952344B (en) Novel protease for treating devitalized tissue
EP1073447A4 (en) N1-MODIFIED GLYCOPEPTIDES
HUP0101947A3 (en) Combination for the treatment of tumors
AP9200355A0 (en) "Therapeutic agent"
ZA979178B (en) Fluorescent whitening agent formulation.
GB9515802D0 (en) Hiv protease inhibitors useful for the treatment of aids
UA32598C2 (uk) Спосіб одержання лікарської форми карбамазепіну
DE69709891D1 (de) Chitosan enthaltende zusammensetzung
AP2000001746A0 (en) Anti- first-pass effect compounds.
EP0912170A4 (en) HIV PROTEASE INHIBITORS USEFUL IN AIDS TREATMENT